Brain atrophy observed in Alzheimer’s disease may be prevented by Ozempic’s drug semaglutide
ZEPHYR/Science Photo Library/Alamy
Ozempic and Wegovy are already transforming treatments for type 2 diabetes and obesity, and next year could add another disease that affects millions of people around the world to the list: Alzheimer’s disease There is.
Two clinical trials investigating Ozempic and Wegovy’s drug semaglutide as a treatment for early Alzheimer’s disease are scheduled to conclude in 2025. If the results are positive, this could lead to breakthroughs in the treatment of this intractable disease.
(Tag translation) Pharmaceuticals
